Ironwood Pharmaceuti (IRWD) 13.37 $IRWD
First Week of February 2017 Options Trading For Ironwood Pharmaceuticals (IRWD)
DividendChannel.com - Tue Jun 21, 10:00AM CDT
Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the February 2017 expiration.
IRWD: 13.37 (+0.25)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 240.59 (+2.58), IRWD: 13.37 (+0.25), AZN: 30.11 (unch), JNP: 7.89 (+0.19)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.37 (+0.25), CPRX: 0.80 (+0.03), AKRX: 30.66 (+0.64), PCRX: 36.39 (+0.53)
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
PR Newswire - Thu Jun 09, 7:01AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the 72 mcg dose of linaclotide for use in the treatment of adults with chronic idiopathic constipation (CIC). The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients with CIC. The FDA Prescription Drug User Fee Act (PDUFA) target action date is expected to occur in early 2017.
AGN: 240.59 (+2.58), IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Mon Jun 06, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 2:30 p.m. Eastern Time in New York City.
IRWD: 13.37 (+0.25)
AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 13.37 (+0.25), ANIP: 56.51 (-1.61), AZN: 30.11 (unch), BMY: 75.28 (+1.20)
Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
BusinessWire - Fri Jun 03, 1:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that it has closed the previously-announced transaction with AstraZeneca for the exclusive U.S. rights to all products containing lesinurad. Lesinurad 200mg tablets were approved as ZURAMPIC(R) by the U.S. Food and Drug Administration (FDA) in December 2015 for use in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. The licensing agreement includes exclusive U.S. rights to the fixed-dose combination of lesinurad and allopurinol. AstraZeneca plans to submit, on Ironwood's behalf, the fixed-dose combination program for FDA regulatory review in the second half of 2016. The agreement also includes certain rights to potentially access RDEA3170 in gout indications in the U.S.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016 at 4:00 p.m. Pacific Time/7:00 p.m. Eastern Time at the Terranea Resort in Rancho Palos Verdes, California.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference
BusinessWire - Wed May 18, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2016 UBS Global Healthcare Conference on Wednesday, May 25, 2016 at 9:00 a.m. Eastern Time at the Grand Hyatt New York.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week(R) 2016
BusinessWire - Tue May 17, 7:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the presentation of linaclotide-related clinical and preclinical data from the company and its collaborators during Digestive Disease Week(R) (DDW) 2016 in San Diego, CA, May 21 through May 24, 2016.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
BusinessWire - Mon May 09, 3:05PM CDT
--- LINZESS(R) (linaclotide) U.S. net sales increased ~44% to $137 million in 1Q 2016 compared to 1Q 2015; on track to exceed $1 billion in net sales by 2020 -
IRWD: 13.37 (+0.25)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 251.30 (+4.03), ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), FLML: 11.36 (+0.22), IRWD: 13.37 (+0.25), GILD: 86.55 (+1.08), AMGN: 161.10 (+4.51), FGEN: 17.76 (+0.63), ENTA: 23.34 (+0.03), NVS: 82.13 (+0.33)
Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What: After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 4.12 (+0.13), AGN: 240.59 (+2.58), IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Tue May 03, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time at the Encore at Wynn Hotel in Las Vegas.
IRWD: 13.37 (+0.25)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ironwood Pharmaceuticals, Inc. (IRWD)
PR Newswire - Thu Apr 28, 1:59PM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Ironwood Pharmaceuticals, Inc. (Ironwood or "the Company) (NASDAQ: IRWD). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
IRWD: 13.37 (+0.25)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ironwood Pharmaceuticals, Inc. - IRWD
PR Newswire - Thu Apr 28, 10:27AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or the "Company"
(NASDAQ: IRWD). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
IRWD: 13.37 (+0.25)
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Ironwood Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Wed Apr 27, 5:10PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Ironwood Pharmaceuticals, Inc. ("Ironwood" or the "Company" (NASDAQ: IRWD). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
IRWD: 13.37 (+0.25)
INVESTOR ALERT: Investigation of Ironwood Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Apr 27, 1:41PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or the "Company" (NASDAQ: IRWD) concerning the Company and its officers' possible violations of federal securities laws.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals Investigated for Potential Violations of Federal Securities Laws by Block & Leviton LLP
PR Newswire - Tue Apr 26, 11:04AM CDT
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Ironwood Pharmaceuticals (NASDAQ: IRWD) and certain of its officers and directors have violated federal securities laws following the publication today by Phase Five Research of a report entitled "Uncovered: fatal safety issues linked with Ironwood's drug, Linzess".
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call
BusinessWire - Mon Apr 25, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2016 investor update conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 9, 2016. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 89241099. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
IRWD: 13.37 (+0.25)
First Week of February 2017 Options Trading For Ironwood Pharmaceuticals (IRWD)
DividendChannel.com - Tue Jun 21, 10:00AM CDT
Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the February 2017 expiration.
IRWD: 13.37 (+0.25)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 240.59 (+2.58), IRWD: 13.37 (+0.25), AZN: 30.11 (unch), JNP: 7.89 (+0.19)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.37 (+0.25), CPRX: 0.80 (+0.03), AKRX: 30.66 (+0.64), PCRX: 36.39 (+0.53)
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
PR Newswire - Thu Jun 09, 7:01AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the 72 mcg dose of linaclotide for use in the treatment of adults with chronic idiopathic constipation (CIC). The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients with CIC. The FDA Prescription Drug User Fee Act (PDUFA) target action date is expected to occur in early 2017.
AGN: 240.59 (+2.58), IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Mon Jun 06, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 2:30 p.m. Eastern Time in New York City.
IRWD: 13.37 (+0.25)
AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 13.37 (+0.25), ANIP: 56.51 (-1.61), AZN: 30.11 (unch), BMY: 75.28 (+1.20)
Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
BusinessWire - Fri Jun 03, 1:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that it has closed the previously-announced transaction with AstraZeneca for the exclusive U.S. rights to all products containing lesinurad. Lesinurad 200mg tablets were approved as ZURAMPIC(R) by the U.S. Food and Drug Administration (FDA) in December 2015 for use in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. The licensing agreement includes exclusive U.S. rights to the fixed-dose combination of lesinurad and allopurinol. AstraZeneca plans to submit, on Ironwood's behalf, the fixed-dose combination program for FDA regulatory review in the second half of 2016. The agreement also includes certain rights to potentially access RDEA3170 in gout indications in the U.S.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016 at 4:00 p.m. Pacific Time/7:00 p.m. Eastern Time at the Terranea Resort in Rancho Palos Verdes, California.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference
BusinessWire - Wed May 18, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2016 UBS Global Healthcare Conference on Wednesday, May 25, 2016 at 9:00 a.m. Eastern Time at the Grand Hyatt New York.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week(R) 2016
BusinessWire - Tue May 17, 7:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the presentation of linaclotide-related clinical and preclinical data from the company and its collaborators during Digestive Disease Week(R) (DDW) 2016 in San Diego, CA, May 21 through May 24, 2016.
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
BusinessWire - Mon May 09, 3:05PM CDT
--- LINZESS(R) (linaclotide) U.S. net sales increased ~44% to $137 million in 1Q 2016 compared to 1Q 2015; on track to exceed $1 billion in net sales by 2020 -
IRWD: 13.37 (+0.25)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 251.30 (+4.03), ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), FLML: 11.36 (+0.22), IRWD: 13.37 (+0.25), GILD: 86.55 (+1.08), AMGN: 161.10 (+4.51), FGEN: 17.76 (+0.63), ENTA: 23.34 (+0.03), NVS: 82.13 (+0.33)
Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What: After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 4.12 (+0.13), AGN: 240.59 (+2.58), IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Tue May 03, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time at the Encore at Wynn Hotel in Las Vegas.
IRWD: 13.37 (+0.25)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ironwood Pharmaceuticals, Inc. (IRWD)
PR Newswire - Thu Apr 28, 1:59PM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Ironwood Pharmaceuticals, Inc. (Ironwood or "the Company) (NASDAQ: IRWD). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
IRWD: 13.37 (+0.25)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ironwood Pharmaceuticals, Inc. - IRWD
PR Newswire - Thu Apr 28, 10:27AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or the "Company"
(NASDAQ: IRWD). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. IRWD: 13.37 (+0.25)
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Ironwood Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Wed Apr 27, 5:10PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Ironwood Pharmaceuticals, Inc. ("Ironwood" or the "Company"
(NASDAQ: IRWD). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. IRWD: 13.37 (+0.25)
INVESTOR ALERT: Investigation of Ironwood Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Apr 27, 1:41PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or the "Company"
(NASDAQ: IRWD) concerning the Company and its officers' possible violations of federal securities laws. IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals Investigated for Potential Violations of Federal Securities Laws by Block & Leviton LLP
PR Newswire - Tue Apr 26, 11:04AM CDT
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Ironwood Pharmaceuticals (NASDAQ: IRWD) and certain of its officers and directors have violated federal securities laws following the publication today by Phase Five Research of a report entitled "Uncovered: fatal safety issues linked with Ironwood's drug, Linzess".
IRWD: 13.37 (+0.25)
Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call
BusinessWire - Mon Apr 25, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2016 investor update conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 9, 2016. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 89241099. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
IRWD: 13.37 (+0.25)
